Syrrx and MolSoft form strategic alliance

Syrrx uses an array of proprietary robotic technologies to automate and streamline multiple steps in the protein structure determination process, resulting in the determination of hundreds of protein structures each year. MolSoft's technology then takes Syrrx discoveries one step closer to medical breakthroughs by using protein structures to create novel drugs. MolSoft's VLS technology uses a supercomputer to simulate the interaction between proteins (i.e., potential drug targets) and small molecules (i.e., potential drugs). The proteins and small molecules are then "fitted" together in the computer to identify those small molecules that might become future drugs. More than 1 million compounds can be tested each day using MolSoft technology. "Our new algorithms are trained to solve the global energy optimization problem of highly complex systems," commented Maxim Totrov, Molsoft's Principal Scientist and scientific co-founder. "Syrrx's robotics," added Wendell Wierenga, CEO of Syrrx, "leveraged together with MolSoft's VLS technology, uniquely positions Syrrx to assume the lead in the structural proteomics space, and, ultimately, to design drugs rapidly."

MolSoft has been developing breakthrough software tools for molecular modeling, bioinformatics, and computer-aided drug discovery since 1994. MolSoft's technology is used by major academic institutions, government organizations, and pharmaceutical companies, including the Genomics Institute of the Novartis Research Foundation, the National Institutes of Health, the Karolinska Institute (Sweden), New York University, Structural Bioinformatics Inc., eBioinformatics, Pharmacia, SmithKline Beecham, and Bristol-Myers Squibb.